FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280611069> ?p ?o ?g. }

• W4280611069 endingPage "365" @default.
• W4280611069 startingPage "356" @default.
• W4280611069 abstract "Nanoparticles (NPs) modified with targeting ligands have often shown great potential in targeted drug delivery for tumor therapy. However, the clearance of NPs by the monocyte-phagocyte system (MPS) and the relatively low cellular uptake by tumor cells have significantly limited the antitumor efficacy of a variety of nanomedicines. Tumor microenvironment-mediated multidrug resistance also reduces the antitumor efficacy of internalized nanomedicines. Herein, we developed an innovative nanomedicine for combined chemo-photodynamic therapy of melanoma through targeted drug delivery and significantly improved the cellular uptake of the nanomedicine through the charge-reversal phenomenon. An amphiphilic platinum (IV)-polyethylenimine-chlorin e6 (Pt(IV)-PEI-Ce6) polymer was designed, prepared, and self-assembled into NPs (PPC) in an aqueous solution, and these NPs were subsequently coated with hyaluronic acid (HA) to afford PPC@HA. The surface-coated HA provided PPC with a negatively charged surface potential to reduce the clearance by the MPS during systemic circulation and enhanced the targeted delivery of PPC to CD44-overexpressing melanoma cells. Upon accumulation in the tumor site, hyaluronidase overexpressed in the tumor induced HA degradation to release the positively charged PPC, resulting in an increased internalization of PPC into tumor cells. Bioactive Pt(II) was released in response to high glutathione level in the tumor cells for effective tumor chemotherapy. Under 650 nm laser irradiation, Ce6 produced reactive oxygen species (ROS), thus driving photodynamic therapy. Finally, PPC@HA exhibited combined photodynamic-chemotherapeutic antitumor efficacy against the melanoma cells in mice. STATEMENT OF SIGNIFICANCE: Tumors are one of the greatest threats to human health, and chemotherapy has been one of the most common therapeutic modalities for treating tumors; however, many challenges related to chemotherapy remain, such as low delivery efficiency, side effects, and unsatisfactory therapeutic efficacy. Nanomedicines modified with targeting ligands have often shown great potential in improving targeted drug delivery for tumor therapy; however, the clearance of nanomaterials by the monocyte-phagocyte system and the relatively low cellular uptake by tumor cells have significantly limited the antitumor efficacy of a variety of nanomedicines. Herein, we developed a novel charge-reversal-based, hyaluronic acid-coated, Pt(IV) prodrug and chlorin e6-based nanomedicine to improve systemic circulation and targeted accumulation of the nanomedicine in the tumor tissue and to enhance its intracellular uptake. This nanomedicine may provide a potential new platform to improve the drug content inside tumor cells and to effectively inhibit tumor growth through combined chemotherapy and photodynamic therapy." @default.
• W4280611069 created "2022-05-22" @default.
• W4280611069 creator A5012134946 @default.
• W4280611069 creator A5019799826 @default.
• W4280611069 creator A5020076735 @default.
• W4280611069 creator A5027416136 @default.
• W4280611069 creator A5027416269 @default.
• W4280611069 creator A5032392257 @default.
• W4280611069 creator A5056745280 @default.
• W4280611069 creator A5062246049 @default.
• W4280611069 creator A5065504437 @default.
• W4280611069 date "2022-07-01" @default.
• W4280611069 modified "2023-10-17" @default.
• W4280611069 title "Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment" @default.
• W4280611069 cites W2035950553 @default.
• W4280611069 cites W2135106949 @default.
• W4280611069 cites W2272216542 @default.
• W4280611069 cites W2294999722 @default.
• W4280611069 cites W2335812415 @default.
• W4280611069 cites W2342772553 @default.
• W4280611069 cites W2559899567 @default.
• W4280611069 cites W2592483717 @default.
• W4280611069 cites W2604994737 @default.
• W4280611069 cites W2736922162 @default.
• W4280611069 cites W2741349883 @default.
• W4280611069 cites W2745610816 @default.
• W4280611069 cites W2762585192 @default.
• W4280611069 cites W2764028271 @default.
• W4280611069 cites W2796552195 @default.
• W4280611069 cites W2884304605 @default.
• W4280611069 cites W2897979644 @default.
• W4280611069 cites W2909182310 @default.
• W4280611069 cites W2917735202 @default.
• W4280611069 cites W2995692931 @default.
• W4280611069 cites W2997279876 @default.
• W4280611069 cites W3010010038 @default.
• W4280611069 cites W3013209441 @default.
• W4280611069 cites W3020891743 @default.
• W4280611069 cites W3036131095 @default.
• W4280611069 cites W3045794306 @default.
• W4280611069 cites W3156543632 @default.
• W4280611069 cites W3165261906 @default.
• W4280611069 cites W3165902289 @default.
• W4280611069 doi "https://doi.org/10.1016/j.actbio.2022.05.015" @default.
• W4280611069 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35577046" @default.
• W4280611069 hasPublicationYear "2022" @default.
• W4280611069 type Work @default.
• W4280611069 citedByCount "14" @default.
• W4280611069 countsByYear W42806110692022 @default.
• W4280611069 countsByYear W42806110692023 @default.
• W4280611069 crossrefType "journal-article" @default.
• W4280611069 hasAuthorship W4280611069A5012134946 @default.
• W4280611069 hasAuthorship W4280611069A5019799826 @default.
• W4280611069 hasAuthorship W4280611069A5020076735 @default.
• W4280611069 hasAuthorship W4280611069A5027416136 @default.
• W4280611069 hasAuthorship W4280611069A5027416269 @default.
• W4280611069 hasAuthorship W4280611069A5032392257 @default.
• W4280611069 hasAuthorship W4280611069A5056745280 @default.
• W4280611069 hasAuthorship W4280611069A5062246049 @default.
• W4280611069 hasAuthorship W4280611069A5065504437 @default.
• W4280611069 hasConcept C105702510 @default.
• W4280611069 hasConcept C126322002 @default.
• W4280611069 hasConcept C126511603 @default.
• W4280611069 hasConcept C15083742 @default.
• W4280611069 hasConcept C155672457 @default.
• W4280611069 hasConcept C171250308 @default.
• W4280611069 hasConcept C178790620 @default.
• W4280611069 hasConcept C18150654 @default.
• W4280611069 hasConcept C185592680 @default.
• W4280611069 hasConcept C192562407 @default.
• W4280611069 hasConcept C2776107976 @default.
• W4280611069 hasConcept C2776694085 @default.
• W4280611069 hasConcept C2777529286 @default.
• W4280611069 hasConcept C2777658100 @default.
• W4280611069 hasConcept C2779820397 @default.
• W4280611069 hasConcept C2781303535 @default.
• W4280611069 hasConcept C2781323092 @default.
• W4280611069 hasConcept C3020616263 @default.
• W4280611069 hasConcept C502942594 @default.
• W4280611069 hasConcept C71924100 @default.
• W4280611069 hasConcept C98274493 @default.
• W4280611069 hasConceptScore W4280611069C105702510 @default.
• W4280611069 hasConceptScore W4280611069C126322002 @default.
• W4280611069 hasConceptScore W4280611069C126511603 @default.
• W4280611069 hasConceptScore W4280611069C15083742 @default.
• W4280611069 hasConceptScore W4280611069C155672457 @default.
• W4280611069 hasConceptScore W4280611069C171250308 @default.
• W4280611069 hasConceptScore W4280611069C178790620 @default.
• W4280611069 hasConceptScore W4280611069C18150654 @default.
• W4280611069 hasConceptScore W4280611069C185592680 @default.
• W4280611069 hasConceptScore W4280611069C192562407 @default.
• W4280611069 hasConceptScore W4280611069C2776107976 @default.
• W4280611069 hasConceptScore W4280611069C2776694085 @default.
• W4280611069 hasConceptScore W4280611069C2777529286 @default.
• W4280611069 hasConceptScore W4280611069C2777658100 @default.
• W4280611069 hasConceptScore W4280611069C2779820397 @default.
• W4280611069 hasConceptScore W4280611069C2781303535 @default.
• W4280611069 hasConceptScore W4280611069C2781323092 @default.

• next